Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -15.16M | -14.26M | -14.01M | -14.26M | -14.42M |
| Total Depreciation and Amortization | 151.60K | 150.80K | 149.70K | 148.30K | 97.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.34M | 1.61M | 1.78M | 1.96M | 2.20M |
| Change in Net Operating Assets | 39.10K | -1.56M | -1.12M | -611.90K | -14.90K |
| Cash from Operations | -13.63M | -14.06M | -13.20M | -12.77M | -12.14M |
| Capital Expenditure | -20.70K | -22.60K | -36.80K | -27.90K | -20.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -562.90K | -867.10K | -921.50K | 207.00K | -636.80K |
| Cash from Investing | -583.50K | -889.60K | -958.10K | 179.30K | -657.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 299.80K | 366.70K |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -2.48M | -3.42M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 0.00 | 0.00 | 0.00 | -2.18M | -3.06M |
| Foreign Exchange rate Adjustments | -13.70K | 6.10K | -17.90K | -10.60K | -19.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.23M | -14.94M | -14.17M | -14.78M | -15.87M |